Income Statement BioMarin Pharmaceutical Inc.

Stocks

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2026 am IST			5-day change	1st Jan Change
59.59 ^USD	-0.68%		+0.79%	+0.27%

13/07	Biomarin Pharmaceutical Inc. Receives Fda Acceptance of Supplemental New Drug Application for Full Approval of Voxzogo for Children with Achondroplasia	CI
13/07	BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia	MT

485fae3534b4b2035f5f807d88b7a976.Hz1OMEunEAkKRAFWKzb-ouvIpJ-n4hbM33bTk-dG75w.a3c6HTOWVEFwI1gxTwC9m9qk993lu1-qkTen4ZQyush7WCJjMtInPHN9RA

Published financial data: BIOMARIN PHARMACEUTICAL INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	184.63Cr	209.6Cr	241.92Cr	285.39Cr	322.13Cr
Total Revenues	184.63Cr	209.6Cr	241.92Cr	285.39Cr	322.13Cr
Cost of Goods Sold, Total	109.93Cr	113.33Cr	126.16Cr	132.74Cr	152.02Cr
Gross Profit	75Cr	96Cr	115.76Cr	152.65Cr	170.11Cr
Selling General & Admin Expenses, Total	76Cr	85Cr	92Cr	91Cr	103.1Cr
Amortization of Goodwill and Intangible Assets - (IS)	6.19Cr	6.28Cr	6.22Cr	4.33Cr	1.94Cr
Other Operating Expenses, Total	82Cr	92Cr	99Cr	96Cr	105.04Cr
Operating Income	-7.43Cr	4.6Cr	17Cr	57Cr	65Cr
Interest Expense, Total	-1.53Cr	-1.6Cr	-1.73Cr	-1.27Cr	-1.09Cr
Interest And Investment Income	1.05Cr	1.8Cr	5.83Cr	7.49Cr	7.49Cr
Net Interest Expenses	-48.55L	20.64L	4.1Cr	6.22Cr	6.4Cr
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	-	-	-	-86L	-
Other Non Operating Income (Expenses)	1.18Cr	-20.5L	1.4Cr	39.32L	89.97L
EBT, Excl. Unusual Items	-6.73Cr	4.6Cr	23Cr	63Cr	72Cr
Restructuring Charges	-	-	-	-9.58Cr	-24Cr
Gain (Loss) On Sale Of Investments	-	-	-1.26Cr	-	-
Gain (Loss) On Sale Of Assets	-	11Cr	-	1Cr	-
Asset Writedown	-	-	-1.4Cr	-	-
In Process R&D Expenses	-	-	-	-	-
Other Unusual Items	-80.26L	-43.99L	-1.19Cr	-	-
EBT, Incl. Unusual Items	-7.54Cr	15Cr	19Cr	54Cr	48Cr
Income Tax Expense	-1.13Cr	80.15L	2.09Cr	11Cr	13Cr
Earnings From Continuing Operations	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Net Income to Company	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Net Income - (IS)	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Net Income to Common Incl Extra Items	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Net Income to Common Excl. Extra Items	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Per Share Items
Net EPS - Basic	-0.35	0.76	0.89	2.25	1.82
Basic EPS - Continuing Operations	-0.35	0.76	0.89	2.25	1.82
Basic Weighted Average Shares Outstanding	18Cr	19Cr	19Cr	19Cr	19Cr
Net EPS - Diluted	-0.35	0.75	0.87	2.21	1.8
Diluted EPS - Continuing Operations	-0.35	0.75	0.87	2.21	1.8
Diluted Weighted Average Shares Outstanding	18Cr	19Cr	19Cr	20Cr	20Cr
Normalized Basic EPS	-0.23	0.16	0.76	2.06	2.36
Normalized Diluted EPS	-0.23	0.15	0.74	1.99	2.29
Supplemental Items
EBITDA	3.37Cr	15Cr	28Cr	67Cr	72Cr
EBITA	-1.24Cr	11Cr	23Cr	61Cr	67Cr
EBIT	-7.43Cr	4.6Cr	17Cr	57Cr	65Cr
EBITDAR	4.77Cr	16Cr	29Cr	68Cr	73Cr
Total Revenues (As Reported)	184.63Cr	209.6Cr	241.92Cr	285.39Cr	322.13Cr
Effective Tax Rate - (Ratio)	14.96	5.36	11.09	21.21	27.69
Current Domestic Taxes	-7L	1.79Cr	3.02Cr	4.12Cr	4.4Cr
Current Foreign Taxes	50.37L	4.22Cr	3.57Cr	1.77Cr	4.09Cr
Total Current Taxes	43.38L	6.01Cr	6.59Cr	5.88Cr	8.48Cr
Deferred Domestic Taxes	-3.11Cr	-8.44Cr	-7.88Cr	-72.83L	4L
Deferred Foreign Taxes	1.55Cr	3.23Cr	3.38Cr	6.34Cr	4.84Cr
Total Deferred Taxes	-1.56Cr	-5.21Cr	-4.5Cr	5.61Cr	4.87Cr
Normalized Net Income	-4.21Cr	2.87Cr	14Cr	39Cr	45Cr
Interest on Long-Term Debt	1.53Cr	1.6Cr	1.73Cr	1.27Cr	1.09Cr
Supplemental Operating Expense Items
Advertising Expense	-	-	2.78Cr	3.45Cr	5.05Cr
Selling and Marketing Expenses	-	-	2.78Cr	3.45Cr	5.05Cr
Research And Development Expense From Footnotes	63Cr	65Cr	75Cr	75Cr	93Cr
Net Rental Expense, Total	1.4Cr	1.37Cr	1.42Cr	1.42Cr	1.13Cr
Imputed Operating Lease Interest Expense	15.2L	15.57L	17.47L	16.23L	15.47L
Imputed Operating Lease Depreciation	1.24Cr	1.21Cr	1.24Cr	1.25Cr	97.83L
Stock-Based Comp., COGS (Total)	8.96Cr	7.94Cr	8.33Cr	7.47Cr	6.89Cr
Stock-Based Comp., SG&A Exp. (Total)	11Cr	12Cr	12Cr	13Cr	11Cr
Total Stock-Based Compensation	20Cr	20Cr	21Cr	20Cr	18Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	59Cr	72Cr	76Cr	94Cr	131.17Cr
Short Term Investments	43Cr	57Cr	32Cr	19Cr	25Cr
Total Cash And Short Term Investments	101.39Cr	129.15Cr	107.38Cr	113.77Cr	156.06Cr
Accounts Receivable, Total	37Cr	46Cr	63Cr	66Cr	91Cr
Total Receivables	37Cr	46Cr	63Cr	66Cr	91Cr
Inventory	78Cr	89Cr	110.72Cr	123.27Cr	129.89Cr
Other Current Assets, Total	11Cr	10Cr	14Cr	20Cr	19Cr
Total Current Assets	227.44Cr	275.15Cr	295.61Cr	323.24Cr	395.35Cr
Gross Property Plant And Equipment	180.25Cr	191.65Cr	197.93Cr	196.86Cr	206.61Cr
Accumulated Depreciation	-72Cr	-80Cr	-87Cr	-89Cr	-107.43Cr
Net Property Plant And Equipment	108.19Cr	111.43Cr	111.22Cr	107.68Cr	99Cr
Long-term Investments	54Cr	37Cr	62Cr	53Cr	49Cr
Goodwill	20Cr	20Cr	20Cr	20Cr	20Cr
Other Intangibles, Total	39Cr	34Cr	33Cr	33Cr	31Cr
Deferred Tax Assets Long-Term	144.91Cr	150.54Cr	154.58Cr	148.94Cr	150.87Cr
Other Long-Term Assets, Total	7.62Cr	9.88Cr	8.36Cr	14Cr	14Cr
Total Assets	600.33Cr	637.51Cr	684.16Cr	698.89Cr	759.4Cr
Liabilities
Accounts Payable, Total	19Cr	23Cr	32Cr	24Cr	31Cr
Accrued Expenses, Total	27Cr	29Cr	31Cr	33Cr	39Cr
Current Portion of Long-Term Debt	-	-	49Cr	-	-
Current Portion of Leases	1.05Cr	1.04Cr	87.79L	75.74L	86.85L
Current Income Taxes Payable	12.13L	1.62Cr	26.51L	1.26Cr	36.67L
Unearned Revenue Current, Total	69.56L	7L	46.2L	13.69L	-
Other Current Liabilities	5.86Cr	3.68Cr	4Cr	1.88Cr	3.96Cr
Total Current Liabilities	54Cr	59Cr	117.7Cr	61Cr	76Cr
Long-Term Debt	107.91Cr	108.3Cr	59Cr	60Cr	60Cr
Long-Term Leases	3.38Cr	2.65Cr	3.81Cr	3.13Cr	3.7Cr
Other Non Current Liabilities	7.98Cr	7.35Cr	8.18Cr	9.76Cr	11Cr
Total Liabilities	173.26Cr	177.19Cr	189.01Cr	133.1Cr	150.7Cr
Common Stock, Total	2L	2L	2L	2L	2L
Additional Paid In Capital	519.15Cr	540.49Cr	561.16Cr	580.21Cr	595.66Cr
Retained Earnings	-93Cr	-79Cr	-62Cr	-19Cr	15Cr
Comprehensive Income and Other	47.43L	-1.27Cr	-3.86Cr	5.04Cr	-2.4Cr
Total Common Equity	427.07Cr	460.32Cr	495.15Cr	565.8Cr	608.7Cr
Total Equity	427.07Cr	460.32Cr	495.15Cr	565.8Cr	608.7Cr
Total Liabilities And Equity	600.33Cr	637.51Cr	684.16Cr	698.89Cr	759.4Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	18Cr	19Cr	19Cr	19Cr	19Cr
ECS Total Common Shares Outstanding	18Cr	19Cr	19Cr	19Cr	19Cr
Book Value / Share	23.22	24.71	26.25	29.66	31.65
Tangible Book Value	368.59Cr	406.84Cr	443Cr	513.44Cr	558Cr
Tangible Book Value Per Share	20.04	21.84	23.49	26.92	29.02
Total Debt	112.34Cr	111.99Cr	113.39Cr	63Cr	64Cr
Net Debt	11Cr	-17Cr	6.01Cr	-50Cr	-92Cr
Debt Equivalent of Unfunded Proj. Benefit Obligation	2.6Cr	2.25Cr	3.01Cr	3.79Cr	4.55Cr
Debt Equivalent Oper. Leases	11Cr	11Cr	11Cr	11Cr	9.06Cr
Account Code - Inventory Valuation	6	6	6	6	3
Inventories - Raw Materials, Total	8.03Cr	13Cr	16Cr	15Cr	11Cr
Inventories - Work In Process, Total	42Cr	41Cr	57Cr	55Cr	80Cr
Inventories - Finished Goods, Total	28Cr	35Cr	38Cr	53Cr	39Cr
Land - (BS)	9.04Cr	9.08Cr	9.08Cr	9.08Cr	9.08Cr
Buildings, Total	77Cr	82Cr	86Cr	89Cr	91Cr
Machinery, Total	69Cr	74Cr	80Cr	79Cr	82Cr
Full Time Employees	3.04T	3.08T	3.4T	3.04T	3.22T
Accumulated Allowance for Doubtful Accounts (Supple)	-	-	-	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-6.41Cr	14Cr	17Cr	43Cr	35Cr
Depreciation & Amortization - CF	4.61Cr	3.92Cr	4.22Cr	5.31Cr	5.28Cr
Amortization of Goodwill and Intangible Assets - (CF)	6.19Cr	6.28Cr	6.22Cr	4.33Cr	1.94Cr
Depreciation & Amortization, Total	11Cr	10Cr	10Cr	9.64Cr	7.22Cr
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	74L
(Gain) Loss From Sale Of Asset	-	-11Cr	-	-1Cr	-
(Gain) Loss on Sale of Investments - (CF)	51.55L	30.43L	-92.28L	-83.45L	-48.01L
Asset Writedown & Restructuring Costs	-	-	3.86Cr	1.99Cr	35Cr
Stock-Based Compensation (CF)	20Cr	20Cr	21Cr	20Cr	18Cr
Other Operating Activities, Total	-78.75L	-6.26Cr	-1.27Cr	6.28Cr	17Cr
Change In Accounts Receivable	6.56Cr	-8.2Cr	-19Cr	-5.79Cr	-23Cr
Change In Inventories	-3.51Cr	-6.83Cr	-16Cr	-6.35Cr	-12Cr
Change In Accounts Payable	1.57Cr	5.9Cr	6.89Cr	-3.22Cr	6.61Cr
Change in Other Net Operating Assets	1.98Cr	-51.04L	-5.79Cr	-6.27Cr	-1.48Cr
Cash from Operations	30Cr	18Cr	16Cr	57Cr	83Cr
Capital Expenditure	-9.56Cr	-12Cr	-9.67Cr	-8.54Cr	-10Cr
Cash Acquisitions	-	-	-	-	-29Cr
Sale (Purchase) of Intangible assets	-2.36Cr	9.27Cr	-1.09Cr	-19.94L	-79.37L
Investment in Marketable and Equity Securities, Total	-25Cr	81.86L	-36.33L	22Cr	-1.81Cr
Other Investing Activities, Total	-10L	-	-	11.41L	-
Cash from Investing	-37Cr	-2Cr	-11Cr	14Cr	-41Cr
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-30.39L	-26.05L	-22.86L	-49Cr	-
Total Debt Repaid	-30.39L	-26.05L	-22.86L	-49Cr	-
Issuance of Common Stock	4.92Cr	6.93Cr	6.94Cr	4.93Cr	1.45Cr
Repurchase of Common Stock	-4.58Cr	-5.43Cr	-7.63Cr	-7.76Cr	-5.6Cr
Other Financing Activities, Total	-4L	-3.11Cr	-94.75L	-31.77L	-9L
Cash from Financing	-48T	-1.86Cr	-1.87Cr	-53Cr	-4.24Cr
Foreign Exchange Rate Adjustments	-57T	32T	13.08L	48.3L	-25.21L
Net Change in Cash	-6.19Cr	14Cr	3.06Cr	19Cr	37Cr
Supplemental Items
Cash Interest Paid	1.04Cr	1.03Cr	1.03Cr	1.04Cr	72.45L
Cash Income Tax Paid (Refund)	1.82Cr	5.44Cr	7.33Cr	5.73Cr	9.62Cr
Levered Free Cash Flow	19Cr	13Cr	-2.59Cr	27Cr	40Cr
Unlevered Free Cash Flow	20Cr	14Cr	-1.51Cr	28Cr	41Cr
Change In Net Working Capital	-6.49Cr	16Cr	33Cr	29Cr	15Cr
Net Debt Issued / Repaid	-30.39L	-26.05L	-22.86L	-49Cr	-

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-0.78	0.46	1.63	5.15	5.58
Return on Total Capital	-0.87	0.52	1.82	5.76	6.25
Return On Equity %	-1.53	3.19	3.51	8.05	5.94
Return on Common Equity	-1.53	3.19	3.51	8.05	5.94
Margin Analysis
Gross Profit Margin %	40.46	45.93	47.85	53.49	52.81
SG&A Margin	41.13	40.74	38.16	32	32.01
EBITDA Margin %	1.83	7.06	11.43	23.35	22.44
EBITA Margin %	-0.67	5.19	9.68	21.49	20.8
EBIT Margin %	-4.03	2.19	7.11	19.97	20.2
Income From Continuing Operations Margin %	-3.47	6.75	6.93	14.96	10.83
Net Income Margin %	-3.47	6.75	6.93	14.96	10.83
Net Avail. For Common Margin %	-3.47	6.75	6.93	14.96	10.83
Normalized Net Income Margin	-2.28	1.37	5.87	13.74	14.04
Levered Free Cash Flow Margin	10.56	6.29	-1.07	9.51	12.5
Unlevered Free Cash Flow Margin	11.08	6.77	-0.62	9.79	12.71
Asset Turnover
Asset Turnover	0.31	0.34	0.37	0.41	0.44
Fixed Assets Turnover	1.7	1.91	2.17	2.61	3.11
Receivables Turnover (Average Receivables)	4.49	5.02	4.42	4.41	4.11
Inventory Turnover (Average Inventory)	1.49	1.36	1.26	1.13	1.2
Short Term Liquidity
Current Ratio	4.21	4.67	2.51	5.33	5.21
Quick Ratio	2.57	2.98	1.45	2.96	3.25
Operating Cash Flow to Current Liabilities	0.56	0.3	0.14	0.94	1.09
Days Sales Outstanding (Average Receivables)	81.23	72.68	82.61	82.99	88.88
Days Outstanding Inventory (Average Inventory)	244.91	269.05	289.49	322.57	303.92
Average Days Payable Outstanding	59.59	62.88	67.66	69.39	63.06
Cash Conversion Cycle (Average Days)	266.55	278.85	304.44	336.17	329.73
Long Term Solvency
Total Debt/Equity	26.3	24.33	22.9	11.2	10.56
Total Debt / Total Capital	20.83	19.57	18.63	10.08	9.55
LT Debt/Equity	26.06	24.1	12.75	11.07	10.42
Long-Term Debt / Total Capital	20.63	19.39	10.37	9.96	9.42
Total Liabilities / Total Assets	28.86	27.79	27.63	19.04	19.84
EBIT / Interest Expense	-4.85	2.88	9.93	45.01	59.71
EBITDA / Interest Expense	3.11	10.12	16.77	53.74	67.37
(EBITDA - Capex) / Interest Expense	-3.12	2.54	11.19	46.99	57.91
Total Debt / EBITDA	23.56	6.93	3.9	0.93	0.88
Net Debt / EBITDA	2.3	-1.06	0.21	-0.74	-1.25
Total Debt / (EBITDA - Capex)	-23.46	27.56	5.85	1.07	1.02
Net Debt / (EBITDA - Capex)	-2.29	-4.22	0.31	-0.85	-1.45
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-0.76	13.53	15.42	17.97	12.87
Gross Profit, 1 Yr. Growth %	5.49	28.89	20.24	33.86	11.44
EBITDA, 1 Yr. Growth %	151.45	338.65	61.75	129.69	26.68
EBITA, 1 Yr. Growth %	-58	-976.05	77.82	147.34	29.49
EBIT, 1 Yr. Growth %	-19.01	-161.85	149.55	206.85	37.22
Earnings From Cont. Operations, 1 Yr. Growth %	-107.46	-320.91	18.43	154.62	-18.26
Net Income, 1 Yr. Growth %	-107.46	-320.91	18.43	154.62	-18.26
Normalized Net Income, 1 Yr. Growth %	-31.21	-168.29	229.19	211.98	36.1
Diluted EPS Before Extra, 1 Yr. Growth %	-107.74	-314.01	16	153.71	-18.24
Accounts Receivable, 1 Yr. Growth %	-16.72	23.54	37.37	4.23	37.5
Inventory, 1 Yr. Growth %	11.18	15.12	23.83	11.33	5.37
Net Property, Plant and Equip., 1 Yr. Growth %	-0.71	3	-0.19	-3.18	-7.89
Total Assets, 1 Yr. Growth %	2.66	6.17	7.32	2.15	8.66
Tangible Book Value, 1 Yr. Growth %	5.54	10.53	8.89	15.9	8.54
Common Equity, 1 Yr. Growth %	4.01	7.91	7.57	14.27	7.58
Cash From Operations, 1 Yr. Growth %	256.75	-42.24	-9.46	259.69	44.54
Capital Expenditures, 1 Yr. Growth %	-16.39	26.56	-20.06	-11.65	20.62
Levered Free Cash Flow, 1 Yr. Growth %	-1.14T	-34.59	-117.71	-1.67T	89.89
Unlevered Free Cash Flow, 1 Yr. Growth %	-45.45T	-32.83	-109.64	-4.39T	86.15
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	4.09	6.14	14.47	16.69	15.39
Gross Profit, 2 Yr. CAGR %	8.92	16.61	24.49	27.2	22.13
EBITDA, 2 Yr. CAGR %	772.5	232.11	186.33	106.27	57.84
EBITA, 2 Yr. CAGR %	-50.83	91.82	334.42	128.49	64.39
EBIT, 2 Yr. CAGR %	-15.81	-29.23	52.18	222.88	87.16
Earnings From Cont. Operations, 2 Yr. CAGR %	63.92	-59.29	61.75	73.65	44.26
Net Income, 2 Yr. CAGR %	63.92	-59.29	61.75	73.65	44.26
Normalized Net Income, 2 Yr. CAGR %	-17.62	-31.46	83.65	280.8	95.91
Diluted EPS Before Extra, 2 Yr. CAGR %	62.2	-59.17	57.56	71.55	44.03
Accounts Receivable, 2 Yr. CAGR %	-0.53	1.44	30.27	19.66	19.72
Inventory, 2 Yr. CAGR %	6.85	13.13	19.4	17.42	8.31
Net Property, Plant and Equip., 2 Yr. CAGR %	0.54	1.13	1.39	-1.7	-5.57
Total Assets, 2 Yr. CAGR %	13.14	4.41	6.74	4.7	5.36
Tangible Book Value, 2 Yr. CAGR %	22.19	7.93	9.71	12.34	12.23
Common Equity, 2 Yr. CAGR %	16.95	5.88	7.74	10.87	10.87
Cash From Operations, 2 Yr. CAGR %	151.2	43.55	-27.68	80.46	128.01
Capital Expenditures, 2 Yr. CAGR %	-18.82	2.87	0.58	-15.96	3.23
Levered Free Cash Flow, 2 Yr. CAGR %	20.98	165.07	-64.16	40.62	381.74
Unlevered Free Cash Flow, 2 Yr. CAGR %	31.36	1.67T	-73.29	37.74	692.71
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	7.38	7.15	9.15	15.62	15.4
Gross Profit, 3 Yr. CAGR %	15.91	15.21	17.8	26.9	21.71
EBITDA, 3 Yr. CAGR %	-17.17	593.77	174.19	170.36	66.49
EBITA, 3 Yr. CAGR %	-53.66	28.42	99.38	266.93	78.68
EBIT, 3 Yr. CAGR %	-21.74	-24.04	23.32	97.22	128.31
Earnings From Cont. Operations, 3 Yr. CAGR %	-6.02	81.06	-41.88	88.16	35.08
Net Income, 3 Yr. CAGR %	-6.02	81.06	-41.88	88.16	35.08
Normalized Net Income, 3 Yr. CAGR %	-27.16	-22.62	32.38	110.46	155.72
Diluted EPS Before Extra, 3 Yr. CAGR %	-7.27	77.9	-42.17	84.68	34
Accounts Receivable, 3 Yr. CAGR %	2.91	6.92	12.22	20.94	25.33
Inventory, 3 Yr. CAGR %	13.52	9.54	16.59	16.65	13.26
Net Property, Plant and Equip., 3 Yr. CAGR %	4.48	1.35	0.69	-0.16	-3.81
Total Assets, 3 Yr. CAGR %	10.69	10.77	5.37	5.19	6.01
Tangible Book Value, 3 Yr. CAGR %	17.38	18.12	8.25	11.73	11.11
Common Equity, 3 Yr. CAGR %	12.9	13.81	6.44	9.87	9.76
Cash From Operations, 3 Yr. CAGR %	147	53.89	23.1	23.44	67.59
Capital Expenditures, 3 Yr. CAGR %	-12.9	-5.87	-5.43	-3.67	-5.2
Levered Free Cash Flow, 3 Yr. CAGR %	42.5	-0.33	11.33	10.44	43.13
Unlevered Free Cash Flow, 3 Yr. CAGR %	72.16	6.17	222.05	9.79	40.61
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	10.58	9.8	10.16	10.86	11.6
Gross Profit, 5 Yr. CAGR %	24.94	15.86	19.27	19.38	19.16
EBITDA, 5 Yr. CAGR %	-27.17	28.95	36.03	331.99	121.98
EBITA, 5 Yr. CAGR %	-44.29	3.15	13.44	64.22	86.68
EBIT, 5 Yr. CAGR %	-22.24	-17.95	2.11	40.3	47.96
Earnings From Cont. Operations, 5 Yr. CAGR %	-36.69	3.88	16.77	78.06	-16.39
Net Income, 5 Yr. CAGR %	-36.69	3.88	16.77	78.06	-16.39
Normalized Net Income, 5 Yr. CAGR %	-25.28	-20.85	5.44	44.62	49.21
Diluted EPS Before Extra, 5 Yr. CAGR %	-37.95	2.25	14.63	75.34	-16.7
Accounts Receivable, 5 Yr. CAGR %	11.64	12.03	13.09	11.85	15.16
Inventory, 5 Yr. CAGR %	16.94	13.45	15.84	12.62	13.21
Net Property, Plant and Equip., 5 Yr. CAGR %	6.26	4.44	3.23	0.12	-1.86
Total Assets, 5 Yr. CAGR %	8.33	6.59	9.1	8.3	5.36
Tangible Book Value, 5 Yr. CAGR %	12.83	14.2	14.22	15.77	9.82
Common Equity, 5 Yr. CAGR %	9.07	10.39	10.78	12.63	8.19
Cash From Operations, 5 Yr. CAGR %	5.97	82.21	51.12	64.02	57.52
Capital Expenditures, 5 Yr. CAGR %	-8.42	-9.5	-7.74	-10.04	-2.06
Levered Free Cash Flow, 5 Yr. CAGR %	-6.21	6.53	-17.4	15.31	84.63
Unlevered Free Cash Flow, 5 Yr. CAGR %	-3.47	15.36	-17.77	18.71	290.49